loading page

A simplified alternative diagnostic algorithm for SARS-CoV-2 suspected symptomatic patients and confirmed close contacts (asymptomatic): A consensus of Latin American experts
  • +7
  • Fabian F. Fay ,
  • Carlos Arturo Alvarez-Moreno,
  • Pablo E Bonvehi,
  • Carolina Cucho Espinoza,
  • Marco Luis Herrera Hidalgo,
  • Marcel Marcano-Lozada,
  • Carlos M. Perez,
  • Alvaro Pulchinelli,
  • Vinicio Klever Sáenz-Flor,
  • Antonio Condino-Neto
Fabian F. Fay
CIBIC Laboratories, Rosario, Argentina
Carlos Arturo Alvarez-Moreno
Bogota, Colombia, Clinica Colsanitas, Clinica Universitaria Colombia, Faculty of Medicine, National University of Colombia
Pablo E Bonvehi
Infectious Diseases Unit, Clinical Investigation and Medical Education Center Buenos Aires, Argentina
Carolina Cucho Espinoza
School of Medicine, National University of San Marcos, Dos de Mayo Hospital Lima, Peru
Marco Luis Herrera Hidalgo
University of Medical Sciences San Jose, Costa Rica
Marcel Marcano-Lozada
Juan Pablo II University San Jose, Costa Rica, Angios Vascular Center and Wound Clinic Caracas, Venezuela
Carlos M. Perez
Faculty of Medicine and Science, San Sebastian University, Clínica Universidad de los Andes Santiago, Chile
Alvaro Pulchinelli
São Paulo, Brazil, Fleury Medicina e Saúde Laboratory , Brazilian Society of Clinical Pathology, Federal University of São Paulo
Vinicio Klever Sáenz-Flor
School of Medicine, University of Equator Quito, Ecuador
Antonio Condino-Neto
São Paulo, Brazil, Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo


Latin America accounts for roughly one-quarter of global COVID-19 cases and one-third of deaths. Health inequalities in the region lead to barriers regarding the best use of diagnostic tests during the pandemic. There is a need for a simplified guideline in the region that takes into consideration the available health resources, international guidelines, medical literature, and local expertise.
Nine experts from different Latin American countries developed a simplified algorithm for COVID-19 diagnosis in the region, using a modified Delphi method. Twenty-four questions related to diverse diagnostic settings were initially proposed, followed by an extensive discussion of the literature and experts' experience.
According to time from close contact or symptom onset, the algorithm considers three different timeframes (≤7 days, 8–13 days, and ≥14 days) and discusses diagnostic options for each one. SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) continues to be the diagnostic test of choice from Day 1 to Day 14 after symptom onset or close contact, although antigen testing may be used in high-prevalence settings or in particular situations (such as from Day 0 to Days 5–7 of symptom onset). Antibody assays may be used for diagnostic confirmation, mainly after Day 14, if there is an epidemiological or individual need. If the clinical suspicion is very high, but other tests are negative, these assays may be used as an adjunct to decision-making from Days 8–13.
The proposed algorithm is intended to be used as a support for COVID-19 diagnosis decision-making in Latin America.
Apr 2022Published in International Journal of Infectious Diseases volume 117 on pages 130-136. 10.1016/j.ijid.2021.05.011